scPharmaceuticals
SCPH
SCPH was delisted on the 6th of October, 2025.
58 hedge funds and large institutions have $152M invested in scPharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 20 increasing their positions, 8 reducing their positions, and 6 closing their positions.
317% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 6
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
150% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 8
66% more capital invested
Capital invested by funds: $91.3M → $152M (+$60.7M)
45% more funds holding
Funds holding: 40 → 58 (+18)
11.07% more ownership
Funds ownership: 51.18% → 62.25% (+11%)
56% less call options, than puts
Call options by funds: $302K | Put options by funds: $693K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$11.3M |
| 2 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$11M |
| 3 |
PA
Perceptive Advisors
New York
|
+$5.82M |
| 4 |
Millennium Management
New York
|
+$4.89M |
| 5 |
O
OrbiMed
New York
|
+$4.66M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
5VM
5AM Venture Management
San Francisco,
California
|
-$3.67M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
-$3.13M |
| 3 |
AC
Armistice Capital
New York
|
-$2.1M |
| 4 |
Belvedere Trading
Chicago,
Illinois
|
-$661K |
| 5 |
BFM
Boothbay Fund Management
New York
|
-$164K |
SCPH Hedge Fund Activity: Q4 2022 in Review
58 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in scPharmaceuticals (SCPH) for Q4 2022, worth a combined $152M — up 66% from $91.3M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new SCPH positions and 6 closed out — a net gain of 19 holders — while 20 added to existing stakes and 8 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $11.3M. The largest seller was 5AM Venture Management, cutting an estimated $3.67M.
- 58 institutional investors held scPharmaceuticals (SCPH) as of Q4 2022, up from 40 in Q3 2022.
- Funds reported $152M of scPharmaceuticals stock for Q4 2022, up 66% quarter-over-quarter.
- 25 funds opened new scPharmaceuticals positions in Q4 2022 and 6 closed out, a net change of +19 holders.
- The largest scPharmaceuticals buyer in Q4 2022 was RA Capital Management, an estimated $11.3M added.
- The largest scPharmaceuticals seller in Q4 2022 was 5AM Venture Management, an estimated $3.67M sold.
Based on aggregated 13F filings for Q4 2022.